BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 29059470)

  • 1. Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma.
    Shen Q; Eun JW; Lee K; Kim HS; Yang HD; Kim SY; Lee EK; Kim T; Kang K; Kim S; Min DH; Oh SN; Lee YJ; Moon H; Ro SW; Park WS; Lee JY; Nam SW
    Hepatology; 2018 Apr; 67(4):1360-1377. PubMed ID: 29059470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SF3B4 as an early-stage diagnostic marker and driver of hepatocellular carcinoma.
    Shen Q; Nam SW
    BMB Rep; 2018 Feb; 51(2):57-58. PubMed ID: 29397868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SF3B4 is regulated by microRNA-133b and promotes cell proliferation and metastasis in hepatocellular carcinoma.
    Liu Z; Li W; Pang Y; Zhou Z; Liu S; Cheng K; Qin Q; Jia Y; Liu S
    EBioMedicine; 2018 Dec; 38():57-68. PubMed ID: 30391496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating small extracellular vesicle-derived splicing factor 3b subunit 4 as a non-invasive diagnostic biomarker of early hepatocellular carcinoma.
    Son JA; Weon JH; Baek GO; Ahn HR; Choi JY; Yoon MG; Cho HJ; Cheong JY; Eun JW; Kim SS
    J Exp Clin Cancer Res; 2023 Oct; 42(1):288. PubMed ID: 37899451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases.
    Yeh MM; Larson AM; Campbell JS; Fausto N; Rulyak SJ; Swanson PE
    Am J Surg Pathol; 2007 May; 31(5):681-9. PubMed ID: 17460450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enabled homolog (ENAH) regulated by RNA binding protein splicing factor 3b subunit 4 (SF3B4) exacerbates the proliferation, invasion and migration of hepatocellular carcinoma cells via Notch signaling pathway.
    Deng G; Luo Y; Zhang Y; Zhang J; He Z
    Bioengineered; 2022 Feb; 13(2):2194-2206. PubMed ID: 35030977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on precursor and early lesions of hepatocellular carcinomas.
    Park YN
    Arch Pathol Lab Med; 2011 Jun; 135(6):704-15. PubMed ID: 21631263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global proteomic profiling in multistep hepatocarcinogenesis and identification of PARP1 as a novel molecular marker in hepatocellular carcinoma.
    Xu X; Liu Z; Wang J; Xie H; Li J; Cao J; Zhou L; Zheng S
    Oncotarget; 2016 Mar; 7(12):13730-41. PubMed ID: 26883192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma.
    Inoue M; Takahashi Y; Fujii T; Kitagawa M; Fukusato T
    World J Gastroenterol; 2014 Dec; 20(46):17541-51. PubMed ID: 25516669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma.
    Yao M; Yao DF; Bian YZ; Zhang CG; Qiu LW; Wu W; Sai WL; Yang JL; Zhang HJ
    Hepatobiliary Pancreat Dis Int; 2011 Jun; 10(3):289-94. PubMed ID: 21669573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SRSF3 Depletion Leads to an Increase in SF3B4 Expression in SNU-368 HCC Cells.
    Lee J; Seo G; Hur W; Yoon SK; Nam SW; Lee JH
    Anticancer Res; 2020 Apr; 40(4):2033-2042. PubMed ID: 32234894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Copy Number of the Gene Encoding SF3B4 Indicates Poor Prognosis in Hepatocellular Carcinoma.
    Iguchi T; Komatsu H; Masuda T; Nambara S; Kidogami S; Ogawa Y; Hu Q; Saito T; Hirata H; Sakimura S; Uchi R; Hayashi N; Ito S; Eguchi H; Sugimachi K; Maehara Y; Mimori K
    Anticancer Res; 2016 May; 36(5):2139-44. PubMed ID: 27127115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition.
    Wang TH; Yu CC; Lin YS; Chen TC; Yeh CT; Liang KH; Shieh TM; Chen CY; Hsueh C
    Oncotarget; 2016 Jul; 7(28):43588-43603. PubMed ID: 27248828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
    Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
    Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
    Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
    Tátrai P
    Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection.
    Noda T; Yamamoto H; Takemasa I; Yamada D; Uemura M; Wada H; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
    Liver Int; 2012 Jan; 32(1):110-8. PubMed ID: 22098155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules.
    Luo Q; Zhang Y; Wang N; Jin G; Jin H; Gu D; Tao X; Huo X; Ge T; Cong W; Wang C; Qin W
    Oncotarget; 2015 Mar; 6(9):6989-99. PubMed ID: 25749520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance.
    Claudio PP; Russo G; Kumar CA; Minimo C; Farina A; Tutton S; Nuzzo G; Giuliante F; Angeloni G; Maria V; Vecchio FM; Campli CD; Giordano A
    Clin Cancer Res; 2004 May; 10(10):3509-17. PubMed ID: 15161709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte-Specific Arid1a Deficiency Initiates Mouse Steatohepatitis and Hepatocellular Carcinoma.
    Fang JZ; Li C; Liu XY; Hu TT; Fan ZS; Han ZG
    PLoS One; 2015; 10(11):e0143042. PubMed ID: 26569409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.